Interim Trial Data Hints at Efficacy of ANVS401
ANVS401, an investigational therapy for neurodegenerative diseases being developed by Annovis Bio, improved the speed and coordination of people with Parkinson’s disease in a Phase 2a clinical trial, an interim analysis suggests. “The results from this interim analysis are very encouraging. This brings us one step closer to…